Navigation Links
Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
Date:12/7/2009

b>Disease) trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

Results of the PIX301 phase III trial presented demonstrated improvement across primary and secondary endpoints of the study at a minimum of nine-month follow-up from end of treatment. Pixantrone produced CR / CRu rate of 25.7% versus 7.1% for the comparator arm, p-value = 0.005. Overall response rate also increased significantly in patients that received pixantrone (40.0% pixantrone arm versus 14.3%, p-value=0.001). Median PFS increased 115% to 5.6 months for pixantrone arm compared to 2.6 for comparator arm, p-value = 0.002 and HR=0.56. Additionally, a positive trend was seen in overall survival with a 48% increase in median overall survival for the pixantrone arm (10.2 months) versus the comparator arm (6.9 months).

Results presented also included a patient subgroup analysis demonstrating that complete response (CR), partial response (PR) and PFS were robust irrespective of risk factors or prior therapy. Pixantrone also provided superior disease control rates over comparator arm with 22 of comparator recipients progressing within the first evaluation point versus 14 for pixantrone recipients.

Despite 50% of patients exceeding cumulative lifetime anthracycline limits (501 - 900 mg/m2), only two cases of congestive heart failure on independent cardiologist assessment were attributed to pixantrone, occurring at lowest drug exposure (<501mg/m2). The follow-up period for the study is ongoing.

"We are pleased that the PIX 301 EXTEND trial of pixantrone not only met its study objective but c
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
2. Pixantrone Now Available in Europe on a Named-Patient Basis
3. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
4. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
7. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
8. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
9. Stem cell research produces a key discovery for Fragile X Syndrome
10. Taxol with avastin produces noteworthy results
11. Aggressive Therapy for Crohns Disease Produces Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... holiday party season fast approaching, a new study reveals that ... arrests have fewer drunk drivers on their roads. The ... vigilantly are better able to deter inebriated revelers from getting ... new laws are being passed regarding drinking and driving," said ...
(Date:12/15/2014)... A recent survey found that the ... impacting skin health and beauty were: “Connections,” “climate,” “career” ... Water and health advocate and radio host Sharon Kleyne ... the survey and the Four C’s.* Kleyne notes, however, ... discussed would benefit from paying attention to one’s daily ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first ... study providing evidence on the impact of 100% pure ... Sufficient enough evidence already exists showing a negative link ... with the onset of tooth decay. One question that ... 100% fruit juice, meaning it is completely natural with ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... & Public Policy Center and the Coalition for ... "get personalized medicine right," Health and Human Services ... implement a reasonable and responsible regulatory framework" for ... diverse coalition of more than a hundred organizations ...
... HARBOR, N.Y. (May 5, 2009) The ... provide a supportive yet flexible framework that allows vertebrates ... knowledge about the vertebrate skeleton, especially recent research on ... a new monograph, The Skeletal System . ...
... CITY, Mo., May 5 Argus Health Systems, Inc., ... announced that Laura Topor has been elected to the ... Trustees for a three-year term. The Board of Trustees ... Council industry standardization development activities. Prior to the election, ...
... May 5 The National Federation of the Blind (NFB) ... Motown group Martha and the Vandellas, will take the stage ... The third annual Motor City ... of July 6, 2009, as part of the National Federation ...
... Bates County Memorial Hospital (BCMH), a ... the MedGenix financial and patient management system. The MedGenix ... cycle management and financial accounting modules. The MedGenix ... Systems (CHS), based in Springfield, MO. Founded in 1992, ...
... Inc. (OTC Bulletin Board: AEMD) today disclosed new ... the Aethlon Hemopurifier(R) to treat Human Immunodeficiency Virus ... Syndrome (AIDS). Aethlon announced that an HIV-infected ... span of one month, had an average viral ...
Cached Medicine News:Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 2Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 3Health News:New book summarizes current knowledge on the biology of the vertebrate skeleton 2Health News:Martha Reeves to Participate in the National Federation of the Blind Motor City March for Independence 2Health News:MedGenix Financial Information System Selected by Bates County Memorial Hospital 2Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 2Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 3Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 4Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 5
(Date:12/15/2014)... Texas , Dec. 15, 2014  Stephen Squires, ... manufacturer Quantum Materials Corp (OTCQB:QTMM), will be ... for Quantum Materials (RCQM) on December 16th, 2014. The ... of exotic nanomaterials in attracting top faculty and students ... to collaborate on research. "We have ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... and development company, is pleased to announce the grant ... States relating to its GPCR-focused drug discovery ... significantly strengthens the global patent estate covering Heptares, technologies ... The suite of patents recently granted by the US ...
(Date:12/13/2014)... , December 12, 2014 ... announced the addition of the  "Global Catheters ... Share, Global Trends, Company Profiles, Analysis, Segmentation ... to their offering.       (Logo: ... made up of medical grade material such ...
Breaking Medicine Technology:Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Global Catheters Market (Product Types and Geography) - Forecast to 2020 2Global Catheters Market (Product Types and Geography) - Forecast to 2020 3
... July 31 , Massachusetts lawmakers passed legislation that includes limited ... , , ... mandatory minimum sentences at county Houses of Correction will have greater access ... on did not include two reforms previously endorsed by the Senate: allowing ...
... , July 30 Conatus Pharmaceuticals Inc. announced ... terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company ... , , ... J. Mento , Ph.D., the former CEO of Idun Pharmaceuticals, which was ...
Cached Medicine Technology:FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
... watt xenon Light Source. ... your commitment to provide every ... care available through our ongoing ... surgical instruments and diagnostic solutions., ...
The new X7000 light source is specifically tuned for the demanding requirements of Progressive Scan High Definition. The X7000 Lightsource uses a 300 Watt Xenon Elliptical Bulb for crystal clear illu...
... 175 watt xenon Light ... , ,SOLOS Endoscopy shares ... patient with the highest quality ... research and development of advanced ...
... need to standardize your video equipment has ... of optical couplers to accommodate all of ... "C and "V mount couplers in both ... designs. We also offer a 20-42mm Zoom ...
Medicine Products: